Osvyrti and Jubereq (denosumab-desu) are developed and commercialized by Accord Biopharma, the specialty division of Intas Pharmaceuticals, Ltd. Boncresa and Oziltus (denosumab-mobz) are from Amneal Pharmaceuticals and mAbxience, the latter being a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma.

The approval of Osvyrti and Jubereq was supported by two clinical trials. A Phase I pharmacokinetic (PK) study in healthy adult males demonstrated comparable PK parameters between Jubereq and Xgeva. A Phase III study in postmenopausal women with osteoporosis found Osvyrti to be highly similar to Prolia, with no clinically meaningful differences in pharmacokinetics, pharmacodynamics, safety, or efficacy.

The dual approvals mark Accord BioPharma's fourth and fifth biosimilars, demonstrating the company's continued growth in the US market. This expansion includes its assumption of US commercial operations for the Udenyca (pegfilgrastim-cbqv) franchise in early 2025 [1]. Accord's biosimilar portfolio also includes Imuldosa (ustekinumab-srlf) [2], referencing Stelara, and Hercessi (trastuzumab-strf), referencing Herceptin [3].

Related article
FDA approves Amneal’s bevacizumab biosimilar

References
1. GaBI Online - Generics and Biosimilars Initiative. Coherus exits the biosimilars market with sale of Udenyca to Intas Pharmaceuticals [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Jan 7]. Available from: www.gabionline.net/pharma-news/coherus-exits-the-biosimilars-market-with-sale-of-udenyca-to-intas-pharmaceuticals
2. GaBI Online - Generics and Biosimilars Initiative. FDA approves fifth ustekinumab biosimilar Imuldosa [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Jan 7]. Available from: www.gabionline.net/biosimilars/news/fda-approves-fifth-ustekinumab-biosimilar-imuldosa
3. GaBI Online - Generics and Biosimilars Initiative. FDA approves fifth ustekinumab biosimilar Imuldosa [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Jan 7]. Available from: www.gabionline.net/biosimilars/news/fda-approves-fifth-ustekinumab-biosimilar-imuldosa

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2025 Pro Pharma Communications International. All Rights Reserved.